Correlation Between Recursion Pharmaceuticals and SCHWAB
Specify exactly 2 symbols:
By analyzing existing cross correlation between Recursion Pharmaceuticals and SCHWAB CHARLES P, you can compare the effects of market volatilities on Recursion Pharmaceuticals and SCHWAB and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Recursion Pharmaceuticals with a short position of SCHWAB. Check out your portfolio center. Please also check ongoing floating volatility patterns of Recursion Pharmaceuticals and SCHWAB.
Diversification Opportunities for Recursion Pharmaceuticals and SCHWAB
0.0 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Recursion and SCHWAB is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Recursion Pharmaceuticals and SCHWAB CHARLES P in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SCHWAB CHARLES P and Recursion Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Recursion Pharmaceuticals are associated (or correlated) with SCHWAB. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SCHWAB CHARLES P has no effect on the direction of Recursion Pharmaceuticals i.e., Recursion Pharmaceuticals and SCHWAB go up and down completely randomly.
Pair Corralation between Recursion Pharmaceuticals and SCHWAB
Given the investment horizon of 90 days Recursion Pharmaceuticals is expected to generate 11.78 times more return on investment than SCHWAB. However, Recursion Pharmaceuticals is 11.78 times more volatile than SCHWAB CHARLES P. It trades about -0.02 of its potential returns per unit of risk. SCHWAB CHARLES P is currently generating about -0.19 per unit of risk. If you would invest 758.00 in Recursion Pharmaceuticals on September 13, 2024 and sell it today you would lose (60.00) from holding Recursion Pharmaceuticals or give up 7.92% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Flat |
| Strength | Insignificant |
| Accuracy | 95.45% |
| Values | Daily Returns |
Recursion Pharmaceuticals vs. SCHWAB CHARLES P
Performance |
| Timeline |
| Recursion Pharmaceuticals |
| SCHWAB CHARLES P |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Recursion Pharmaceuticals and SCHWAB Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Recursion Pharmaceuticals and SCHWAB
The main advantage of trading using opposite Recursion Pharmaceuticals and SCHWAB positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Recursion Pharmaceuticals position performs unexpectedly, SCHWAB can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SCHWAB will offset losses from the drop in SCHWAB's long position.| Recursion Pharmaceuticals vs. Absci Corp | Recursion Pharmaceuticals vs. Affimed NV | Recursion Pharmaceuticals vs. Sana Biotechnology | Recursion Pharmaceuticals vs. Relay Therapeutics |
| SCHWAB vs. Thor Industries | SCHWAB vs. Wabash National | SCHWAB vs. Magna International | SCHWAB vs. NiSource |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Complementary Tools
| Stocks Directory Find actively traded stocks across global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |